Solid Biosciences Net Worth
Solid Biosciences Net Worth Breakdown | SLDB |
Solid Biosciences Net Worth Analysis
Solid Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Solid Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Solid Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Solid Biosciences' net worth analysis. One common approach is to calculate Solid Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Solid Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Solid Biosciences' net worth. This approach calculates the present value of Solid Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Solid Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Solid Biosciences' net worth. This involves comparing Solid Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Solid Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Solid Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Solid Biosciences' net worth research are outlined below:
| Solid Biosciences had very high historical volatility over the last 90 days | |
| Solid Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (124.7 M) with loss before overhead, payroll, taxes, and interest of (96.43 M). | |
| Solid Biosciences LLC currently holds about 162.88 M in cash with (100.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Solid Biosciences Inc.s market cap dropped US53m last week Private equity firms bore the brunt |
Solid Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Solid Biosciences LLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Solid Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Solid Biosciences Target Price Consensus
Solid target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Solid Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Solid analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Solid stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Solid Biosciences LLC, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSolid Biosciences Target Price Projection
Solid Biosciences' current and average target prices are 4.60 and 16.90, respectively. The current price of Solid Biosciences is the price at which Solid Biosciences LLC is currently trading. On the other hand, Solid Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Solid Biosciences Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On Solid Biosciences Target Price
Know Solid Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Solid Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Solid Biosciences LLC backward and forwards among themselves. Solid Biosciences' institutional investor refers to the entity that pools money to purchase Solid Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2024-12-31 | 719.8 K | Redmile Group, Llc | 2024-12-31 | 615.2 K | Geode Capital Management, Llc | 2024-12-31 | 509.8 K | Monashee Investment Management Llc | 2024-12-31 | 480 K | State Street Corp | 2024-12-31 | 432.2 K | Alyeska Investment Group, L.p. | 2024-12-31 | 346.4 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 264.1 K | Laurion Capital Management Lp | 2024-12-31 | 255.1 K | Nuveen Asset Management, Llc | 2024-12-31 | 197.9 K | Perceptive Advisors Llc | 2024-12-31 | 6.9 M | Ra Capital Management, Llc | 2024-12-31 | 4.3 M |
Follow Solid Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 364.22 M.Market Cap |
|
Project Solid Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (0.91) | (0.86) |
When accessing Solid Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Solid Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Solid Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Solid Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Solid Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Solid Biosciences' management manipulating its earnings.
Evaluate Solid Biosciences' management efficiency
Solid Biosciences LLC has return on total asset (ROA) of (0.4586) % which means that it has lost $0.4586 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9457) %, meaning that it created substantial loss on money invested by shareholders. Solid Biosciences' management efficiency ratios could be used to measure how well Solid Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.69. In addition to that, Return On Capital Employed is expected to decline to -0.86. At present, Solid Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 2.4 M, whereas Total Assets are forecasted to decline to about 157.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.36 | 3.19 | |
| Tangible Book Value Per Share | 3.36 | 3.19 | |
| Enterprise Value Over EBITDA | (0.83) | (0.79) | |
| Price Book Value Ratio | 1.19 | 1.25 | |
| Enterprise Value Multiple | (0.83) | (0.79) | |
| Price Fair Value | 1.19 | 1.25 | |
| Enterprise Value | -93.2 M | -88.5 M |
Management at Solid Biosciences LLC focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Solid Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Solid Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Solid Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Solid Biosciences Corporate Filings
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 6th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 25th of February 2025 Other Reports | ViewVerify | |
F3 | 19th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Solid Biosciences Earnings Estimation Breakdown
The calculation of Solid Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Solid Biosciences is estimated to be -0.541 with the future projection ranging from a low of -0.77 to a high of -0.39. Please be aware that this consensus of annual earnings estimates for Solid Biosciences LLC is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.77 Lowest | Expected EPS | -0.39 Highest |
Solid Biosciences Earnings Projection Consensus
Suppose the current estimates of Solid Biosciences' value are higher than the current market price of the Solid Biosciences stock. In this case, investors may conclude that Solid Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Solid Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 12 | 71.16% | -1.0 | -0.541 | -3.06 |
Solid Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Solid Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Solid Biosciences LLC predict the company's earnings will be in the future. The higher the earnings per share of Solid Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Solid Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Solid Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Solid Biosciences should always be considered in relation to other companies to make a more educated investment decision.Solid Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Solid Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-11 | 2024-12-31 | -0.7822 | -1.0 | -0.2178 | 27 | ||
2024-11-06 | 2024-09-30 | -0.67 | -0.79 | -0.12 | 17 | ||
2024-08-13 | 2024-06-30 | -0.65 | -0.61 | 0.04 | 6 | ||
2024-05-15 | 2024-03-31 | -0.64 | -0.64 | 0.0 | 0 | ||
2024-03-13 | 2023-12-31 | -0.99 | -1.0 | -0.01 | 1 | ||
2023-11-08 | 2023-09-30 | -1.19 | -1.05 | 0.14 | 11 | ||
2023-08-14 | 2023-06-30 | -1.53 | -1.25 | 0.28 | 18 | ||
2023-05-11 | 2023-03-31 | -2.05 | -1.5 | 0.55 | 26 | ||
2023-03-23 | 2022-12-31 | -1.65 | -0.68 | 0.97 | 58 | ||
2022-11-10 | 2022-09-30 | -2.67 | -2.71 | -0.04 | 1 | ||
2022-08-11 | 2022-06-30 | -3.15 | -3.3 | -0.15 | 4 | ||
2022-04-27 | 2022-03-31 | -2.76 | -3.3 | -0.54 | 19 | ||
2022-03-14 | 2021-12-31 | -2.91 | -2.4 | 0.51 | 17 | ||
2021-11-03 | 2021-09-30 | -3.02 | -2.4 | 0.62 | 20 | ||
2021-08-16 | 2021-06-30 | -2.82 | -2.55 | 0.27 | 9 | ||
2021-05-14 | 2021-03-31 | -4.86 | -2.85 | 2.01 | 41 | ||
2021-03-15 | 2020-12-31 | -5.09 | -4.65 | 0.44 | 8 | ||
2020-11-05 | 2020-09-30 | -5.17 | -6.6 | -1.43 | 27 | ||
2020-08-06 | 2020-06-30 | -7.45 | -5.85 | 1.6 | 21 | ||
2020-05-07 | 2020-03-31 | -7.83 | -7.65 | 0.18 | 2 | ||
2020-03-12 | 2019-12-31 | -9.14 | -9.75 | -0.61 | 6 | ||
2019-11-12 | 2019-09-30 | -9.65 | -10.05 | -0.4 | 4 | ||
2019-08-14 | 2019-06-30 | -11.81 | -11.4 | 0.41 | 3 | ||
2019-05-13 | 2019-03-31 | -9.48 | -12.75 | -3.27 | 34 | ||
2019-03-13 | 2018-12-31 | -9.09 | -9.49 | -0.4 | 4 | ||
2018-11-13 | 2018-09-30 | -8.4 | -8.25 | 0.15 | 1 | ||
2018-08-10 | 2018-06-30 | -7.65 | -7.8 | -0.15 | 1 | ||
2018-05-10 | 2018-03-31 | -6.8 | -8.1 | -1.3 | 19 | ||
2018-03-29 | 2017-12-31 | -8.95 | -13.35 | -4.4 | 49 | ||
2017-10-23 | 2017-09-30 | 0 | -0.52 | -0.52 | 0 | ||
2017-02-03 | 2016-12-31 | 0 | -0.14 | -0.14 | 0 |
Solid Biosciences Corporate Executives
Elected by the shareholders, the Solid Biosciences' board of directors comprises two types of representatives: Solid Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Solid. The board's role is to monitor Solid Biosciences' management team and ensure that shareholders' interests are well served. Solid Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Solid Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.